Cantor Fitzgerald has reaffirmed its
Overweight rating and $400 price target on
Elevance Health, Inc. (ELV). An inquiry has been opened by
Grabar Law Office into claims on behalf of long-term shareholders of Elevance Health. There's ambiguity surrounding the company's recent surge amid
ACA Subsidy Negotiation Uncertainty. Q3 2025 results are soon to be reported by Elevance Health. Taking advantage of its low valuation, investors are encouraged to acquire shares in the company, described as an undervalued, defensive colossus with long-term upside potential. Despite this, the company's shares have recently experienced a 12% decline, due to disappointing Q2 results. Over the past year, unfortunate losses of 37% and 42% have been suffered by Elevance Health's investors.
UBS and
Bernstein continue to endorse buying Elevance Health shares due to its steady earnings and growth prospects. Financial investigations suggest the company is undervalued with potential for 16.27% upside. Concerningly, insiders have recently sold $6.7m of the stocks, possibly hinting at prospective weaknesses. Notably, it is being conceptualised that ELV's outreach beyond insurance might serve as a model for future healthcare. Following slashing 2025 outlook on Medicaid weakness, Barclays has enhanced Elevance Health price target from $327 to $373.
Elevance Health ELV News Analytics from Thu, 22 May 2025 07:00:00 GMT to Sat, 04 Oct 2025 14:29:26 GMT -
Rating 0
- Innovation 5
- Information 7
- Rumor -3
